-
1
-
-
66749185880
-
Prevalence and incidence of endocrine and metabolic disorders in the United States: A comprehensive review
-
Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009;94:1853-78.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 1853-1878
-
-
Golden, S.H.1
Robinson, K.A.2
Saldanha, I.3
Anton, B.4
Ladenson, P.W.5
-
2
-
-
33646593777
-
Extent of disease at presentation and outcome for adrenocortical carcinoma: Have we made progress?
-
DOI 10.1007/s00268-005-0329-x
-
Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 2006;30:872-8. (Pubitemid 43724119)
-
(2006)
World Journal of Surgery
, vol.30
, Issue.5
, pp. 872-878
-
-
Kebebew, E.1
Reiff, E.2
Duh, Q.-Y.3
Clark, O.H.4
McMillan, A.5
-
3
-
-
0034917097
-
Adrenocortical carcinomas: Surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group
-
DOI 10.1007/s00268-001-0047-y
-
Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001;25:891-7. (Pubitemid 32666390)
-
(2001)
World Journal of Surgery
, vol.25
, Issue.7
, pp. 891-897
-
-
Icard, P.1
Goudet, P.2
Charpenay, C.3
Andreassian, B.4
Carnaille, B.5
Chapuis, Y.6
Cougard, P.7
Henry, J.-F.8
Proye, C.9
-
4
-
-
33745777816
-
Clinical and biological features in the prognosis of adrenocortical cancer: Poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients
-
DOI 10.1210/jc.2005-2730
-
Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006;91:2650-5. (Pubitemid 44024632)
-
(2006)
Journal of Clinical Endocrinology and Metabolism
, vol.91
, Issue.7
, pp. 2650-2655
-
-
Abiven, G.1
Coste, J.2
Groussin, L.3
Anract, P.4
Tissier, F.5
Legmann, P.6
Dousset, B.7
Bertagna, X.8
Bertherat, J.9
-
5
-
-
33846089053
-
Prognostic parameters of metastatic adrenocortical carcinoma
-
DOI 10.1210/jc.2006-0706
-
Assié G, Antoni G, Tissier F, et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2007;92:148-54. (Pubitemid 46067523)
-
(2007)
Journal of Clinical Endocrinology and Metabolism
, vol.92
, Issue.1
, pp. 148-154
-
-
Assie, G.1
Antoni, G.2
Tissier, F.3
Caillou, B.4
Abiven, G.5
Gicquel, C.6
Leboulleux, S.7
Travagli, J.-P.8
Dromain, C.9
Bertagna, X.10
Bertherat, J.11
Schlumberger, M.12
Baudin, E.13
-
6
-
-
59449084843
-
Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: Proposal for a revised TNM classification
-
Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 2009;115:243-50.
-
(2009)
Cancer
, vol.115
, pp. 243-250
-
-
Fassnacht, M.1
Johanssen, S.2
Quinkler, M.3
-
7
-
-
76049095621
-
The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the International Union Against Cancer staging system: A North American validation
-
Lughezzani G, Sun M, Perrotte P, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the International Union Against Cancer staging system: a North American validation. Eur J Cancer 2010;46:713-9.
-
(2010)
Eur J Cancer
, vol.46
, pp. 713-719
-
-
Lughezzani, G.1
Sun, M.2
Perrotte, P.3
-
8
-
-
0028208020
-
Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients
-
Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994;69:947-51. (Pubitemid 24140681)
-
(1994)
British Journal of Cancer
, vol.69
, Issue.5
, pp. 947-951
-
-
Haak, H.R.1
Hermans, J.2
Van De, V.C.J.H.3
Lentjes, E.G.W.M.4
Goslings, B.M.5
Fleuren, G.-J.6
Krans, H.M.J.7
-
9
-
-
0035883416
-
Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma
-
DOI 10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2
-
Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001;92:1385-92. (Pubitemid 32947821)
-
(2001)
Cancer
, vol.92
, Issue.6
, pp. 1385-1392
-
-
Baudin, E.1
Pellegriti, G.2
Bonnay, M.3
Penfornis, A.4
Laplanche, A.5
Vassal, G.6
Schlumberger, M.7
-
10
-
-
34249999500
-
Adjuvant mitotane treatment for adrenocortical carcinoma
-
DOI 10.1056/NEJMoa063360
-
Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356:2372-80. (Pubitemid 46883771)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.23
, pp. 2372-2380
-
-
Terzolo, M.1
Angeli, A.2
Fassnacht, M.3
Daffara, F.4
Tauchmanova, L.5
Conton, P.A.6
Rossetto, R.7
Buci, L.8
Sperone, P.9
Grossrubatscher, E.10
Reimondo, G.11
Bollito, E.12
Papotti, M.13
Saeger, W.14
Hahner, S.15
Koschker, A.-C.16
Arvat, E.17
Ambrosi, B.18
Loli, P.19
Lombardi, G.20
Mannelli, M.21
Bruzzi, P.22
Mantero, F.23
Allolio, B.24
Dogliotti, L.25
Berruti, A.26
more..
-
11
-
-
34249810952
-
Adrenocortical cancer: Pathophysiology and clinical management
-
DOI 10.1677/erc.1.01130
-
Libé R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007;14:13-28. (Pubitemid 47521719)
-
(2007)
Endocrine-Related Cancer
, vol.14
, Issue.1
, pp. 13-28
-
-
Libe, R.1
Fratticci, A.2
Bertherat, J.3
-
13
-
-
80053312970
-
Contemporary management of adrenocortical carcinoma
-
Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol 2011;60:1055-65.
-
(2011)
Eur Urol
, vol.60
, pp. 1055-1065
-
-
Zini, L.1
Porpiglia, F.2
Fassnacht, M.3
-
14
-
-
83955165239
-
Therapeutic management of advanced adrenocortical carcinoma: What do we know in 2011?
-
Baudin E, Leboulleux S, Al Ghuzlan A, et al. Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Horm Cancer 2011;2:363-71.
-
(2011)
Horm Cancer
, vol.2
, pp. 363-371
-
-
Baudin, E.1
Leboulleux, S.2
Al Ghuzlan, A.3
-
15
-
-
17644399691
-
Management of patients with adrenal cancer: Recommendations of an international consensus conference
-
DOI 10.1677/erc.1.01029
-
Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005;12:667-80. (Pubitemid 41483000)
-
(2005)
Endocrine-Related Cancer
, vol.12
, Issue.3
, pp. 667-680
-
-
Schteingart, D.E.1
Doherty, G.M.2
Gauger, P.G.3
Giordano, T.J.4
Hammer, G.D.5
Korobkin, M.6
Worden, F.P.7
-
16
-
-
0032533913
-
Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma
-
DOI 10.1002/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.0. CO;2-3
-
Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Cancer 1998;83:2194-200. (Pubitemid 28525402)
-
(1998)
Cancer
, vol.83
, Issue.10
, pp. 2194-2200
-
-
Berruti, A.1
Terzolo, M.2
Pia, A.3
Angeli, A.4
Dogliotti, L.5
-
17
-
-
0033767891
-
Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: Long-term survival in its adjuvant use
-
Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000;11:1281-7.
-
(2000)
Ann Oncol
, vol.11
, pp. 1281-1287
-
-
Khan, T.S.1
Imam, H.2
Juhlin, C.3
-
18
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
-
(2000)
Journal of the National Cancer Institute
, vol.92
, Issue.3
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
Van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
19
-
-
0034949971
-
Interpreting quality of life data: Population-based reference data for the EORTC QLQ-C30
-
DOI 10.1016/S0959-8049(01)00127-7, PII S0959804901001277
-
Fayers PM. Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30. Eur J Cancer 2001;37:1331-4. (Pubitemid 32588741)
-
(2001)
European Journal of Cancer
, vol.37
, Issue.11
, pp. 1331-1334
-
-
Fayers, P.M.1
-
20
-
-
33646783722
-
-
v2.0. Bethesda, MD: Cancer Therapy Evaluation Program
-
Common Terminology Criteria for Adverse Events (CTCAE) v2.0. Bethesda, MD: Cancer Therapy Evaluation Program, 1999 (http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm).
-
(1999)
Common Terminology Criteria for Adverse Events (CTCAE)
-
-
-
21
-
-
77956352930
-
Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma
-
Malandrino P, Al Ghuzlan A, Castaing M, et al. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer 2010;17:797-807.
-
(2010)
Endocr Relat Cancer
, vol.17
, pp. 797-807
-
-
Malandrino, P.1
Al Ghuzlan, A.2
Castaing, M.3
-
22
-
-
79953193793
-
Mitotane has a strong and a durable inducing effect on CYP3A4 activity
-
van Erp NP, Guchelaar HJ, Ploeger BA, Romijn JA, Hartigh J, Gelderblom H. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol 2011;164:621-6.
-
(2011)
Eur J Endocrinol
, vol.164
, pp. 621-626
-
-
Van Erp, N.P.1
Guchelaar, H.J.2
Ploeger, B.A.3
Romijn, J.A.4
Hartigh, J.5
Gelderblom, H.6
-
23
-
-
80054769146
-
Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma
-
Oxf
-
Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2011;75:585-91.
-
(2011)
Clin Endocrinol
, vol.75
, pp. 585-591
-
-
Kroiss, M.1
Quinkler, M.2
Lutz, W.K.3
Allolio, B.4
Fassnacht, M.5
-
24
-
-
79956306619
-
Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: Results of a retrospective ENS@T multicenter study
-
Hermsen IG, Fassnacht M, Terzolo M, et al. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 2011;96:1844-51.
-
(2011)
J Clin Endocrinol Metab
, vol.96
, pp. 1844-1851
-
-
Hermsen, I.G.1
Fassnacht, M.2
Terzolo, M.3
-
25
-
-
0027465121
-
Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: A Southwest Oncology Group study
-
Bukowski RM, Wolfe M, Levine HS, et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 1993;11:161-5. (Pubitemid 23059990)
-
(1993)
Journal of Clinical Oncology
, vol.11
, Issue.1
, pp. 161-165
-
-
Bukowski, R.M.1
Wolfe, M.2
Levine, H.S.3
Crawford, D.E.4
Stephens, R.L.5
Gaynor, E.6
Harker, W.G.7
-
26
-
-
0034162574
-
Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: A Southwest Oncology Group study
-
DOI 10.1002/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0. CO;2-R
-
Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 2000;88:1159-65. (Pubitemid 30127678)
-
(2000)
Cancer
, vol.88
, Issue.5
, pp. 1159-1165
-
-
Williamson, S.K.1
Lew, D.2
Miller, G.J.3
Balcerzak, S.P.4
Baker, L.H.5
Crawford, E.D.6
-
27
-
-
0036569569
-
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: Continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist
-
DOI 10.1002/cncr.10487
-
Abraham J, Bakke S, Rutt A, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002;94:2333-43. (Pubitemid 34457113)
-
(2002)
Cancer
, vol.94
, Issue.9
, pp. 2333-2343
-
-
Abraham, J.1
Bakke, S.2
Rutt, A.3
Meadows, B.4
Merino, M.5
Alexander, R.6
Schrump, D.7
Bartlett, D.8
Choyke, P.9
Robey, R.10
Hung, E.11
Steinberg, S.M.12
Bates, S.13
Fojo, T.14
-
28
-
-
26944468635
-
Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: A large prospective phase II trial
-
DOI 10.1677/erc.1.01025
-
Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 2005;12:657-66. (Pubitemid 41482999)
-
(2005)
Endocrine-Related Cancer
, vol.12
, Issue.3
, pp. 657-666
-
-
Berruti, A.1
Terzolo, M.2
Sperone, P.3
Pia, A.4
Della, C.S.5
Gross, D.J.6
Carnaghi, C.7
Casali, P.8
Porpiglia, F.9
Mantero, F.10
Reimondo, G.11
Angeli, A.12
Dogliotti, L.13
-
29
-
-
33745067446
-
The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R
-
DOI 10.1677/erc.1.01124
-
Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGFR. Endocr Relat Cancer 2006;13:535-40. (Pubitemid 43886675)
-
(2006)
Endocrine-Related Cancer
, vol.13
, Issue.2
, pp. 535-540
-
-
Gross, D.J.1
Munter, G.2
Bitan, M.3
Siegal, T.4
Gabizon, A.5
Weitzen, R.6
Merimsky, O.7
Ackerstein, A.8
Salmon, A.9
Sella, A.10
Slavin, S.11
-
30
-
-
45149110737
-
Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine
-
DOI 10.1210/jc.2007-2564
-
Quinkler M, Hahner S, Wortmann S, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 2008;93:2057-62. [Erratum, J Clin Endocrinol Metab 2008;93:3230.] (Pubitemid 351831515)
-
(2008)
Journal of Clinical Endocrinology and Metabolism
, vol.93
, Issue.6
, pp. 2057-2062
-
-
Quinkler, M.1
Hahner, S.2
Wortmann, S.3
Johanssen, S.4
Adam, P.5
Ritte, C.6
Strasburger, C.7
Allolio, B.8
Fassnacht, M.9
-
32
-
-
75149143015
-
Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
-
Wortmann S, Quinkler M, Ritter C, et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol 2010;162:349-56.
-
(2010)
Eur J Endocrinol
, vol.162
, pp. 349-356
-
-
Wortmann, S.1
Quinkler, M.2
Ritter, C.3
-
34
-
-
84857943100
-
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma
-
Berruti A, Sperone P, Ferrero A, et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 2012;166:451-8.
-
(2012)
Eur J Endocrinol
, vol.166
, pp. 451-458
-
-
Berruti, A.1
Sperone, P.2
Ferrero, A.3
|